Selskabets formål er at udøve virksomhed indenfor industri og handel samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 417.9 mio. | 16.9 mio. | 197.3 mio. | 35.1 mio. | 128 | |
CVR: 29883718
Secondary names: WARRICK LÆGEMIDLER ApS, ESSEX PHARMA ApS, SCHERING-PLOUGH ANIMAL HEALTH ApS
Compared to 410 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 43707795
CVR 33597037
CVR 40486585
CVR 34352542
CVR 37575003
4 public tenders won
Sources: TED (the EU tender database) and udbud.dk
The financial health of MSD DANMARK ApS shows signs of decline, particularly in revenue and equity. Revenue decreased from 761.5 million DKK in 2021 to 417.9 million DKK in 2025, while profit has also fluctuated, peaking at 26.7 million DKK in 2022 before settling at 16.9 million DKK in 2025. The equity position has significantly dropped from 99.4 million DKK in 2021 to 35.1 million DKK in 2025, indicating potential concerns regarding financial stability. Despite these challenges, the company remains a notable player in the wholesale trade of pharmaceuticals and healthcare products within the industry.
AI-generated summary
companydata.dk